The outcome of COVID-19 in patients with hematological malignancy

[1] Zhou F(2020)Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet 395 1054-1062

[2] Yu T(2020)Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Eur Respir J 55 5-559

[3] Du R(2020)Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis Aging (Albany NY) 12 6049-386

[4] Guan W(2020)COVID-19 and cancer: lessons from a pooled meta-analysis JCO Glob Oncol 6 557-941

[5] Liang W(2020)Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020 MMWR Morb Mortal. Wkly Rep 69 382-e745

[6] Zhao Y(2020)Case fatality rate of cancer patients with COVID-19 in a New York hospital system Cancer Discov 10 935-2040

[7] Wang B(2020)Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study Lancet Haematol 7 e737-544

[8] Li R(2020)COVID-19 and its implications for thrombosis and anticoagulation Blood 135 2033-5975

[9] Lu Z(2019)Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient Infect. Dis. Clin. North Am. 33 523-2374

[10] Desai A(2020)Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub Blood Adv 4 5966-506

[1] Zhou F(2020)Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet 395 1054-1062

[2] Yu T(2020)Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Eur Respir J 55 5-559

[3] Du R(2020)Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis Aging (Albany NY) 12 6049-386

[4] Guan W(2020)COVID-19 and cancer: lessons from a pooled meta-analysis JCO Glob Oncol 6 557-941

[5] Liang W(2020)Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020 MMWR Morb Mortal. Wkly Rep 69 382-e745

[6] Zhao Y(2020)Case fatality rate of cancer patients with COVID-19 in a New York hospital system Cancer Discov 10 935-2040

[7] Wang B(2020)Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study Lancet Haematol 7 e737-544

[8] Li R(2020)COVID-19 and its implications for thrombosis and anticoagulation Blood 135 2033-5975

[9] Lu Z(2019)Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient Infect. Dis. Clin. North Am. 33 523-2374

[10] Desai A(2020)Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub Blood Adv 4 5966-506